Japanese Start-Up Biotech To Use New Ways To Find Antibodies
This article was originally published in PharmAsia News
Executive Summary
Japan's government laboratory and Chiome Bioscience, a startup associated with it, plan to find a new way to search for antibodies that could be developed into drugs and reagents for diagnostics. The procedure planned involves using magnetic beads to sift a pair of antibody-antigen reactions out of a solution using a magnet. The difference between the plan developed by the joint work of Chiome and the government lab Riken and previous methods is the use of a magnet to separate wanted antibodies from unwanted ones. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.